Results 81 to 90 of about 31,440 (256)

Standardized MRI‐Based Quantification of Epicardial Adipose Tissue Volume: Reproducibility and Agreement With Cardiac Computed Tomography

Journal of Magnetic Resonance Imaging, EarlyView.
ABSTRACT Background Epicardial adipose tissue volume (EATV) is increasingly recognized as a cardiometabolic risk marker associated with adverse outcomes. The most established approach for EATV quantification is cardiac computed tomography (CT). MRI offers a radiation‐free alternative allowing simultaneous assessment of myocardial function and tissue ...
Judith Gronwald, Svante S. Gersch, Zoé Böttiger, Clara Hagedorn, Torben Lange, Sören J. Backhaus, Sebastian Kelle, Constanze Schmidt, Karl Toischer, Andreas Schuster, Alexander Schulz   +10 more
wiley   +1 more source

Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends

JEADV Clinical Practice, EarlyView.
ABSTRACT Background There is a growing body of literature suggesting that GLP‐1 receptor agonists (GLP‐1RAs) may be associated with hair loss; however, primary literature is sparse. Additionally, it is not well‐established which types of hair loss may be associated with GLP‐1RA use. Objectives This study aims to assess associations between GLP‐1RAs and
Lauren M. Ching, Christopher A. Guirguis, Joe K. Tung   +2 more
wiley   +1 more source

The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review

Drug Design, Development and Therapy
Zhao Liu,1 Shanshan Yu,1 Xinyan Jin,1 Luguang Sheng,2 Mai Re YanMu,1 Jie Gao,1 Jun Lu,1 Tao Lei1 1Department of Endocrinology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China; 2Department of ...
Liu Z, Yu S, Jin X, Sheng L, YanMu MR, Gao J, Lu J, Lei T   +7 more
doaj  

Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley   +1 more source

GLP-1 and PYY for the treatment of obesity: a pilot study on the use of agonists and antagonists in diet-induced rats

Endocrine Connections
Objective: Combination therapies with gut hormone analogs represent promising treatment strategies for obesity. This pilot study investigates the therapeutic potential of modulators of the glucagon-like peptide 1 (GLP-1) and neuropeptide Y (NPY) system ...
Marie Oertel, Christian G Ziegler, Michael Kohlhaas, Alexander Nickel, Simon Kloock, Christoph Maack, Vasco Sequeira, Martin Fassnacht, Ulrich Dischinger   +8 more
doaj   +1 more source

Olfactory Dysfunction and Metabolic Syndrome Components: A Systematic Review and Meta‐Analysis

The Laryngoscope, EarlyView.
ABSTRACT Objective To elucidate the association between olfactory dysfunction (OD) and metabolic syndrome components. Data Sources PubMed (National Library of Medicine—National Institutes of Health), Scopus (Elsevier), CINAHL Complete (EBSCOhost), and the Cochrane Library (Wiley) databases were searched from inception through March 23rd, 2026.
Neeti Gandra, Kaitlyn A. Roberts, Shaun A. Nguyen, Pete Peters, Lauren A. Howser, Zachary M. Soler, Rodney J. Schlosser   +6 more
wiley   +1 more source

The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties

Medicina
As an incretin hormone, Glucagon-like peptide-1 (GLP-1) has obvious effects on blood glucose regulation and weight loss. GLP-1 receptor (GLP-1R) agonists are synthetic products that have similar effects to GLP-1 but are less prone to degradation, and ...
Chenqi Lu, Cong Xu, Jun Yang
doaj   +1 more source

Efficacy and safety of GLP-1 receptor agonists for adolescents and children with obesity: a meta-analysis of randomized controlled trials

BMC Endocrine Disorders
Objective To evaluate the efficacy and safety of glucagon-like peptide-1 (GLP-1) receptor agonists in the treatment of obesity among children and adolescents.
Qirong Chen, Haixia Liu, Jie Xu, Yu Zhou, Junying Ma   +4 more
doaj   +1 more source

Barriers to glucagon-like peptide-1 agonists used for obesity management among the general population in Tabuk City, Saudi Arabia, and their relation to smoking cessation and antidepressants

Frontiers in Pharmacology
BackgroundObesity is a chronic inflammatory disease with high morbidity that is decidedly prevalent worldwide and in Saudi Arabia. Glucagon-like peptide 1 receptor agonists (GLP-1 agonists) are broadly used for the management of diabetes and obesity.
Amirah Alhowiti, Hyder Mirghani, Abdulaziz Abdulrahman Qrmli, Amal Abdullah Albalawi, Raneem Abdulrahman Aljohani   +4 more
doaj   +1 more source

Precision Medicine in Neurodegeneration with Brain Iron Accumulation (NBIA) Disorders: An Update on Emerging Treatments

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Neurodegeneration with Brain Iron Accumulation (NBIA) is a heterogeneous group of heritable, mostly recessive, progressive neurodegenerative diseases characterized by iron deposition in the basal ganglia and brainstem. There are no solid global epidemiological data on prevalence and incidence of NBIA subtypes, but registry data and ...
Susanne A. Schneider, Divyani Garg, Vassilena Iankova, Thomas Klopstock   +3 more
wiley   +1 more source